# Special Situations Watchlist — Catalyst-Driven Plays
## Matt Hoffmann Tactical Sleeve
## Date: 2026-05-09 | Generated by Midas 🪙

---

## Purpose
Build disciplined 3-12 month positions with **pre-defined exits** to:
1. Heal PLTR scar through systematic wins (not revenge trading)
2. Separate "trading" from "investing" identities
3. Generate repeatable process confidence

---

## Position Sizing Rule
| Parameter | Value |
|-----------|-------|
| Max per name | 3% of total portfolio |
| Max sleeve size | 15% of total portfolio (5 names @ 3%) |
| Min position | 1.5% (must be meaningful, not a toy) |

---

## THE WATCHLIST: 8 Quantified Candidates

### 1. **RIGEL PHARMACEUTICALS (RIGL)** — PDUFA Re-Examination Play
**Sector:** Biotech | **Catalyst:** FDA re-examination of fostamatinib label expansion
**Timeline:** 4-6 months

| Metric | Value |
|--------|-------|
| Current price | ~$0.80-1.00 (microcap, check live) |
| Market cap | ~$150M |
| Cash runway | Q2 2026 earnings to confirm |
| Thesis | ITP drug with potential expansion; FDA has been tough on small biotechs, creating oversold opps |
| **Entry** | Below $1.00 on PDUFA anticipation |
| **Target** | $2.50-3.00 (label expansion approval = 150-200% upside) |
| **Stop** | $0.60 (cash burn + failed appeal thesis invalidation) |
| **Time stop** | September 2026 if no FDA clarity |
| **Position size** | 2% max |
| **Risk rating** | HIGH — microcap binary event |
| **Why it fits** | Matt's healthcare domain knowledge; discrete catalyst; asymmetric if FDA softens stance |

---

### 2. **SOFI TECHNOLOGIES (SOFI)** — GAAP Profitability Inflection
**Sector:** Fintech | **Catalyst:** Sustained GAAP profitability + charter expansion
**Timeline:** 3-6 months (Q2/Q3 earnings)

| Metric | Value |
|--------|-------|
| Current price | ~$7-8 (check live) |
| Market cap | ~$8B |
| Thesis | GAAP profitable since 2024; student loan refinancing engine if policy shifts; tech platform monetization |
| **Entry** | Pullback to 50-day MA (~$7.00) or below |
| **Target** | $12-14 (re-rating to 3-4x sales on profitability proof) |
| **Stop** | $5.50 (loss of profitability + tech spend reacceleration) |
| **Time stop** | December 2026 if no multiple expansion |
| **Position size** | 3% max |
| **Risk rating** | MEDIUM — execution on tech platform, rate sensitivity |
| **Why it fits** | Matt's fintech knowledge; clear earnings catalyst; liquid options for CSPs if desired |

---

### 3. **AFFIRM (AFRM)** — BNPL Profitability + Apple Partnership
**Sector:** Fintech | **Catalyst:** Sustained profitability + Apple Pay integration expansion
**Timeline:** 3-9 months

| Metric | Value |
|--------|-------|
| Current price | ~$55-65 (check live) |
| Market cap | ~$18B |
| Thesis | BNPL market maturing; AFRM first to real profitability; Apple partnership = distribution moat |
| **Entry** | 10% pullback from highs (~$55) or post-earnings dip |
| **Target** | $90-100 (30x forward earnings on 25% growth = market-premium fintech) |
| **Stop** | $42 (recession-driven credit deterioration + delinquency spike) |
| **Time stop** | March 2027 if no Apple expansion announced |
| **Position size** | 3% max |
| **Risk rating** | MEDIUM-HIGH — consumer credit cyclicality |
| **Why it fits** | Matt's fintech competency; consumer discretionary exposure he avoids in core; tactical only |

---

### 4. **CAMECO (CCJ)** — Uranium Contracting Cycle + SMR Demand
**Sector:** Energy / Uranium | **Catalyst:** Utility contracting cycle + SMR deployment announcements
**Timeline:** 6-12 months

| Metric | Value |
|--------|-------|
| Current price | ~$45-50 (check live) |
| Market cap | ~$20B |
| **ALREADY OWNED** | Matt holds 2.2% — this is a POTENTIAL ADD, not new position |
| Thesis | Uranium spot price recovery; 2026-2027 utility contracting window; SMR demand visibility |
| **Entry (for add)** | Only on 20%+ pullback to ~$38-40 |
| **Target (add tranche)** | $65-70 (contracting cycle peak + SMR orders) |
| **Stop (add tranche)** | $32 (uranium spot collapses below $60/lb) |
| **Time stop** | June 2027 if no utility contracts materialize |
| **Position size** | Max total CCJ exposure 4% (2.2% existing + 1.8% add max) |
| **Risk rating** | MEDIUM — commodity cyclicality, geopolitical supply |
| **Why it fits** | Matt already owns; knows thesis; this is a TRIM/ADD framework, not new research |

---

### 5. **OKLO (OKLO)** — SMR Deployment + Regulatory Milestones
**Sector:** Energy / Nuclear | **Catalyst:** NRC licensing decisions + deployment contracts
**Timeline:** 6-12 months

| Metric | Value |
|--------|-------|
| Current price | ~$8-12 (high vol, check live) |
| Market cap | ~$2B |
| Thesis | Sam Altman-backed SMR play; NRC pathway critical; first-mover in advanced reactor commercialization |
| **Entry** | Post-NRC pullback below $10 OR post-positive decision at $12-14 |
| **Target** | $25-30 (NRC approval + first utility contract = re-rating) |
| **Stop** | $6 (NRC denial + funding runway concerns) |
| **Time stop** | December 2026 if no NRC milestone |
| **Position size** | 2% max (speculative, pre-revenue) |
| **Risk rating** | VERY HIGH — regulatory binary, pre-revenue, alt-energy sentiment driven |
| **Why it fits** | Matt's interest in "moonshots"; nuclear aligns with CCJ thesis; discrete regulatory catalyst |

---

### 6. **SUPER MICRO COMPUTER (SMCI)** — AI Server Recovery + Audit Resolution
**Sector:** AI Infrastructure | **Catalyst:** Audit resolution + datacenter capex cycle resumption
**Timeline:** 3-9 months

| Metric | Value |
|--------|-------|
| Current price | ~$35-45 (check live) |
| Market cap | ~$8B |
| Thesis | AI server demand intact; audit overhang temporary; customer concentration (Nvidia ecosystem) = risk and opportunity |
| **Entry** | Post-audit clarity below $40 OR confirmed restatement resolution |
| **Target** | $70-85 (earnings re-rate on clean audit + AI capex resumption) |
| **Stop** | $25 (audit finds material issues + delisting risk) |
| **Time stop** | September 2026 if no 10-K filing |
| **Position size** | 2.5% max |
| **Risk rating** | HIGH — accounting overhang, customer concentration |
| **Why it fits** | Matt's AI/tech domain knowledge; special situation (audit = temporary dislocation); clear resolution timeline |

---

### 7. **VISTRA (VST)** — Nuclear Restart + Grid Reliability Premium
**Sector:** Utility / Energy | **Catalyst:** Nuclear fleet restart completion + grid reliability pricing
**Timeline:** 6-12 months

| Metric | Value |
|--------|-------|
| Current price | ~$100-120 (check live) |
| Market cap | ~$40B |
| Thesis | Largest competitive nuclear fleet; Texas grid volatility = pricing power; nuclear restart timeline |
| **Entry** | 10% pullback to ~$105 OR post-restart confirmation |
| **Target** | $150-170 (nuclear restart + grid premium + multiple expansion) |
| **Stop** | $80 (restart delays + Texas regulatory interference) |
| **Time stop** | June 2027 if restart not complete |
| **Position size** | 3% max |
| **Risk rating** | MEDIUM — utility regulation, execution risk |
| **Why it fits** | Matt holds VPU (utilities ETF); VST is tactical upgrade with nuclear angle; different from "boring" blue chips |

---

### 8. **ROYALTY PHARMA (RPRX)** — Royalty Stream Monetization + Biotech M&A
**Sector:** Biotech / Royalty | **Catalyst:** Portfolio monetization + M&A-driven royalty acceleration
**Timeline:** 6-12 months

| Metric | Value |
|--------|-------|
| Current price | ~$28-32 (check live) |
| Market cap | ~$15B |
| Dividend yield | ~3-4% |
| Thesis | Biotech royalty aggregator; M&A in pharma = royalty acceleration; depressed valuation vs. NAV |
| **Entry** | Below $30 (trading at discount to NAV) |
| **Target** | $42-48 (NAV realization + dividend growth re-rating) |
| **Stop** | $22 (biotech M&A dries up + royalty defaults) |
| **Time stop** | March 2027 if no portfolio monetization |
| **Position size** | 3% max |
| **Risk rating** | MEDIUM — biotech credit risk, M&A cycle dependent |
| **Why it fits** | Matt's healthcare knowledge; yield component = "sleep well"; different structure (royalty, not drug development); M&A catalyst |

---

## RANKED BY CATALYST CLARITY

| Rank | Ticker | Catalyst Clarity | Timeline | Risk | Conviction |
|------|--------|------------------|----------|------|------------|
| 1 | SOFI | GAAP profit + charter = clear | 3-6 mo | Medium | HIGH |
| 2 | RPRX | M&A cycle + NAV discount = quantifiable | 6-12 mo | Medium | HIGH |
| 3 | SMCI | Audit resolution = binary but date-bound | 3-9 mo | High | MEDIUM-HIGH |
| 4 | AFRM | Apple partnership + profitability = event-driven | 3-9 mo | Med-High | MEDIUM |
| 5 | VST | Nuclear restart = infrastructure timeline | 6-12 mo | Medium | MEDIUM |
| 6 | RIGL | PDUFA = pure binary | 4-6 mo | Very High | MEDIUM |
| 7 | OKLO | NRC = regulatory binary | 6-12 mo | Very High | MEDIUM |
| 8 | CCJ (add) | Contracting cycle = commodity timing | 6-12 mo | Medium | MEDIUM |

---

## ANTI-PLTR PROTOCOL: Embedded in Every Position

For ANY tax-loss sale in this sleeve:
1. **Write re-entry plan BEFORE selling** (price, timeline, thesis refresh)
2. **Set calendar reminder** for re-evaluation at 30/60/90 days
3. **If thesis intact** → re-enter regardless of tax loss harvested
4. **If thesis changed** → log why and move on (PLTR lesson = process failure, not intelligence failure)

---

## PSYCHOLOGICAL FRAMEWORK

**This sleeve exists to:**
- Generate wins with DEFINED endpoints (not "hold forever")
- Build confidence in SELLING (not just buying)
- Create separation: TSLA/LLY = conviction holds; Tactical sleeve = process discipline

**Permission structure:**
- 1 tactical win = permission to maintain 1 conviction hold
- 3 tactical wins in a row = options education graduation
- Any tactical loss > stop = PAUSE new entries for 30 days (process review)

---

## IMMEDIATE ACTION ITEMS

1. **Matt to confirm:** Which 3-5 names resonate? (Not all 8)
2. **Pull live prices** for chosen names
3. **Set price alerts** at entry levels
4. **Draft CSP paper trades** for SOFI/AFRM (options-enabled accounts)
5. **Schedule 30-day review** after first entry

---

*Generated by Midas 🪙 | Not investment advice | Quantified analysis only*